Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.

Tranexamic acid does not decrease blood loss during myomectomy

15 Sep 2020

Tranexamic acid administrated intravenously in patients undergoing laparoscopic or robotic myomectomies does not appear to reduce blood loss.

Women with symptomatic fibroids thought to be at risk for large intraoperative blood loss who had at least one fibroid ≥10 cm, any intramural or broad ligament fibroid ≥6 cm, and/or at least five total fibroids based on preoperative imaging were randomized to receive a single intravenous bolus injection of tranexamic acid 15 mg/kg (intervention group) or an intravenous bolus injection of saline of equivalent volume (placebo group) 20 minutes before the initial surgical incision.

The investigators defined perioperative bleeding by measuring intraoperative estimated blood loss, change between pre- and postoperative haemoglobin, and frequency of blood transfusions. They calculated the estimated blood loss by combining the blood volume collected within the suction canister and the weight of used sponges.

Finally, the investigators compared the two groups in terms of age; body mass index (BMI); perioperative haemoglobin and haematocrit; perioperative blood loss; duration of surgery; blood transfusion requirements; and the number, total weight, and volume of myomas removed.

Sixty patients (30 per group) participated in the study between 1 March 2015 and 29 January 2018. Both groups had comparable age, BMI, baseline haemoglobin and/or haematocrit, number and total weight of myomas removed, and myoma size. Of the participants, 32 (53 percent) patients had laparoscopic myomectomy, 24 (40 percent) had robotic myomectomy, and four (7 percent) had laparotomy.

The median estimated blood loss was 200 and 240 mL for the tranexamic acid and placebo group, respectively (p=0.88). No between-group difference was observed in the median duration of surgery (165 vs 164 min; p=0.64) or change in perioperative haemoglobin (1.00 vs 1.1 g/dL; p=0.64).

Blood transfusions were not required among patients in the tranexamic acid group. On the other hand, four patients (13.3 percent) in the placebo group needed blood transfusions (p=0.11).

“Myomectomy is associated with a significant risk of haemorrhage,” the investigators said. “Tranexamic acid is a synthetic lysine derivative with antifibrinolytic activity used in other surgical disciplines to reduce blood loss during surgery.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.